Diagnosis and treatment of Parkinson disease: molecules to medicine - PubMed (original) (raw)
Review
Diagnosis and treatment of Parkinson disease: molecules to medicine
Joseph M Savitt et al. J Clin Invest. 2006 Jul.
Abstract
Parkinson disease (PD) is a relatively common disorder of the nervous system that afflicts patients later in life with tremor, slowness of movement, gait instability, and rigidity. Treatment of these cardinal features of the disease is a success story of modern science and medicine, as a great deal of disability can be alleviated through the pharmacological correction of brain dopamine deficiency. Unfortunately these therapies only provide temporary, though significant, relief from early symptoms and do not halt disease progression. In addition, pathological changes outside of the motor system leading to cognitive, autonomic, and psychiatric symptoms are not sufficiently treated by current therapies. Much as the discovery of dopamine deficiency led to powerful treatments for motor symptoms, recent discoveries concerning the role of specific genes in PD pathology will lead to the next revolution in disease therapy. Understanding why and how susceptible cells in motor and nonmotor regions of the brain die in PD is the first step toward preventing this cell death and curing or slowing the disease. In this review we discuss recent discoveries in the fields of diagnosis and treatment of PD and focus on how a better understanding of disease mechanisms gained through the study of monogenetic forms of PD has provided novel therapeutic targets.
Figures
Figure 1. Model of dopaminergic cell death and possible sites for therapeutic intervention in PD.
Studies on inherited forms of PD have led to the identification of genes that, when mutated, lead to dopaminergic cell loss. These genes are involved in a variety of cellular processes that include protein ubiquitination and degradation via the proteasome, response to oxidative stress, protein phosphorylation, mitochondrial function, and protein folding. Potential points of therapeutic intervention are highlighted: gene silencing therapies to reduce synuclein levels (i); inhibitors of synuclein aggregation and/or processing (ii); interventions to downregulate toxic substrates or upregulate parkin or proteasomal function (iii); interventions to enhance mitochondrial function with factors such as CoQ10, DJ-1, or PINK-1 (iv); free radical scavengers and antioxidants (v); kinase inhibitors to block LRRK2 activity or interventions to increase PINK-1 function (vi); and other therapies using trophic factors such as GDNF, survival genes, or fetal/stem cell replacement that would protect or replace susceptible cells (vii).
Similar articles
- Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H. Büeler H. Exp Neurol. 2009 Aug;218(2):235-46. doi: 10.1016/j.expneurol.2009.03.006. Epub 2009 Mar 18. Exp Neurol. 2009. PMID: 19303005 Review. - [Mitochondrial dysfunction and oxidative damages in the molecular pathology of Parkinson's disease].
Shadrina MI, Slominskiĭ PA. Shadrina MI, et al. Mol Biol (Mosk). 2008 Sep-Oct;42(5):809-19. Mol Biol (Mosk). 2008. PMID: 18988530 Review. Russian. - Parkinson's disease.
Thomas B, Beal MF. Thomas B, et al. Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R183-94. doi: 10.1093/hmg/ddm159. Hum Mol Genet. 2007. PMID: 17911161 Review. - The role of oxidative stress in Parkinson's disease.
Dias V, Junn E, Mouradian MM. Dias V, et al. J Parkinsons Dis. 2013;3(4):461-91. doi: 10.3233/JPD-130230. J Parkinsons Dis. 2013. PMID: 24252804 Free PMC article. Review. - Emerging pathways in genetic Parkinson's disease.
Lewis PA. Lewis PA. FEBS J. 2008 Dec;275(23):5747. doi: 10.1111/j.1742-4658.2008.06706.x. FEBS J. 2008. PMID: 19021751 No abstract available.
Cited by
- Isothiocyanates Are Promising Compounds against Oxidative Stress, Neuroinflammation and Cell Death that May Benefit Neurodegeneration in Parkinson's Disease.
Sita G, Hrelia P, Tarozzi A, Morroni F. Sita G, et al. Int J Mol Sci. 2016 Sep 1;17(9):1454. doi: 10.3390/ijms17091454. Int J Mol Sci. 2016. PMID: 27598127 Free PMC article. Review. - The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease.
Wan OW, Chung KK. Wan OW, et al. PLoS One. 2012;7(6):e38545. doi: 10.1371/journal.pone.0038545. Epub 2012 Jun 12. PLoS One. 2012. PMID: 22701661 Free PMC article. - A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses.
Zha J, Liu XM, Zhu J, Liu SY, Lu S, Xu PX, Yu XL, Liu RT. Zha J, et al. Sci Rep. 2016 Nov 8;6:36631. doi: 10.1038/srep36631. Sci Rep. 2016. PMID: 27824125 Free PMC article. - Animal models of neurodegenerative diseases.
Dawson TM, Golde TE, Lagier-Tourenne C. Dawson TM, et al. Nat Neurosci. 2018 Oct;21(10):1370-1379. doi: 10.1038/s41593-018-0236-8. Epub 2018 Sep 24. Nat Neurosci. 2018. PMID: 30250265 Free PMC article. Review. - Nobiletin Alleviates Astrocyte Activation and Oxidative Stress Induced by Hypoxia In Vitro.
Wang D, Gao F, Hu F, Wu J. Wang D, et al. Molecules. 2022 Mar 17;27(6):1962. doi: 10.3390/molecules27061962. Molecules. 2022. PMID: 35335325 Free PMC article.
References
- Nutt J.G., Wooten G.F. Clinical practice. Diagnosis and initial management of Parkinson’s disease. N. Engl. J. Med. 2005;353:1021–1027. - PubMed
- Elbaz A., et al. Risk tables for parkinsonism and Parkinson’s disease. J. Clin. Epidemiol. 2002;55:25–31. - PubMed
- de Rijk M.C., et al. Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54(Suppl. 5):S21–S23. - PubMed
- Goetz C.G. Parkinson’s disease diagnosis and clinical management. S. Factor and W. Weiner, editors. Demos Medical Publishing.; New York, New York, USA.: 2002. Charcot and Parkinson’s disease. pp. 19–26.
- Brissaud E. Leçons sur les malades nerveuses. Masson.; Paris, France.: 1895. Nature et pathogenie de la maladie de Parkinson. pp. 488–501.
Publication types
MeSH terms
Substances
Grants and funding
- R21 NS051468/NS/NINDS NIH HHS/United States
- K08 NS052624/NS/NINDS NIH HHS/United States
- NS38377/NS/NINDS NIH HHS/United States
- R01 NS048206/NS/NINDS NIH HHS/United States
- NS051468/NS/NINDS NIH HHS/United States
- NS048206/NS/NINDS NIH HHS/United States
- NS054207/NS/NINDS NIH HHS/United States
- NS052624/NS/NINDS NIH HHS/United States
- R21 NS054207/NS/NINDS NIH HHS/United States
- P50 NS038377/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous